JP2022544683A5 - - Google Patents
Info
- Publication number
- JP2022544683A5 JP2022544683A5 JP2022509648A JP2022509648A JP2022544683A5 JP 2022544683 A5 JP2022544683 A5 JP 2022544683A5 JP 2022509648 A JP2022509648 A JP 2022509648A JP 2022509648 A JP2022509648 A JP 2022509648A JP 2022544683 A5 JP2022544683 A5 JP 2022544683A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- fragment
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025152149A JP2026009903A (ja) | 2019-08-16 | 2025-09-12 | 新規な抗ｔｃｒデルタ可変１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1911799.3 | 2019-08-16 | ||
| GBGB1911799.3A GB201911799D0 (en) | 2019-08-16 | 2019-08-16 | Novel Antibodies |
| GBGB2010760.3A GB202010760D0 (en) | 2020-07-13 | 2020-07-13 | Novel antibodies |
| GB2010760.3 | 2020-07-13 | ||
| PCT/GB2020/051955 WO2021032960A1 (en) | 2019-08-16 | 2020-08-14 | Novel anti-tcr delta variable 1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025152149A Division JP2026009903A (ja) | 2019-08-16 | 2025-09-12 | 新規な抗ｔｃｒデルタ可変１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544683A JP2022544683A (ja) | 2022-10-20 |
| JP2022544683A5 true JP2022544683A5 (enExample) | 2023-08-21 |
Family
ID=72148174
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509647A Pending JP2022545196A (ja) | 2019-08-16 | 2020-08-14 | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP2022509648A Pending JP2022544683A (ja) | 2019-08-16 | 2020-08-14 | 新規な抗ｔｃｒデルタ可変１抗体 |
| JP2025113769A Pending JP2025160218A (ja) | 2019-08-16 | 2025-07-04 | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP2025152149A Pending JP2026009903A (ja) | 2019-08-16 | 2025-09-12 | 新規な抗ｔｃｒデルタ可変１抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509647A Pending JP2022545196A (ja) | 2019-08-16 | 2020-08-14 | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113769A Pending JP2025160218A (ja) | 2019-08-16 | 2025-07-04 | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP2025152149A Pending JP2026009903A (ja) | 2019-08-16 | 2025-09-12 | 新規な抗ｔｃｒデルタ可変１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220403025A1 (enExample) |
| EP (2) | EP4013505A1 (enExample) |
| JP (4) | JP2022545196A (enExample) |
| KR (2) | KR20220084019A (enExample) |
| CN (2) | CN114222585A (enExample) |
| AU (4) | AU2020332878B2 (enExample) |
| BR (1) | BR112022002837A2 (enExample) |
| CA (2) | CA3145517A1 (enExample) |
| CL (2) | CL2022000368A1 (enExample) |
| CO (1) | CO2022002001A2 (enExample) |
| IL (1) | IL290537A (enExample) |
| MX (1) | MX2022002075A (enExample) |
| WO (2) | WO2021032960A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| CA3127103A1 (en) | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| ES2943063T5 (en) * | 2020-08-14 | 2026-05-05 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
| EP4147716A1 (en) * | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| CA3208653A1 (en) | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| EP4688851A1 (en) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| CN121752599A (zh) * | 2023-08-31 | 2026-03-27 | 南京传奇生物科技有限公司 | 抗γδTCR抗体及其用途 |
| WO2026087747A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof |
| WO2026087748A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof |
| US20260152558A1 (en) | 2024-11-27 | 2026-06-04 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| CN102295702B (zh) * | 2011-08-26 | 2014-01-29 | 中国科学院微生物研究所 | 一种针对t细胞受体可变区特异性单抗的制备方法 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| PE20190115A1 (es) * | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
| WO2019147735A1 (en) * | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| JP7686571B2 (ja) * | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
-
2020
- 2020-08-14 JP JP2022509647A patent/JP2022545196A/ja active Pending
- 2020-08-14 CA CA3145517A patent/CA3145517A1/en active Pending
- 2020-08-14 BR BR112022002837A patent/BR112022002837A2/pt unknown
- 2020-08-14 KR KR1020227008859A patent/KR20220084019A/ko active Pending
- 2020-08-14 EP EP20758308.9A patent/EP4013505A1/en active Pending
- 2020-08-14 US US17/633,439 patent/US20220403025A1/en active Pending
- 2020-08-14 MX MX2022002075A patent/MX2022002075A/es unknown
- 2020-08-14 EP EP20758305.5A patent/EP4013504A1/en active Pending
- 2020-08-14 WO PCT/GB2020/051955 patent/WO2021032960A1/en not_active Ceased
- 2020-08-14 AU AU2020332878A patent/AU2020332878B2/en active Active
- 2020-08-14 WO PCT/GB2020/051959 patent/WO2021032963A1/en not_active Ceased
- 2020-08-14 CN CN202080057206.1A patent/CN114222585A/zh active Pending
- 2020-08-14 KR KR1020227008860A patent/KR20220084020A/ko active Pending
- 2020-08-14 JP JP2022509648A patent/JP2022544683A/ja active Pending
- 2020-08-14 CA CA3145523A patent/CA3145523A1/en active Pending
- 2020-08-14 CN CN202080065477.1A patent/CN114514245A/zh active Pending
- 2020-08-14 AU AU2020333406A patent/AU2020333406B2/en active Active
-
2022
- 2022-02-10 IL IL290537A patent/IL290537A/en unknown
- 2022-02-15 CL CL2022000368A patent/CL2022000368A1/es unknown
- 2022-02-24 CO CONC2022/0002001A patent/CO2022002001A2/es unknown
-
2024
- 2024-07-25 CL CL2024002250A patent/CL2024002250A1/es unknown
-
2025
- 2025-07-04 JP JP2025113769A patent/JP2025160218A/ja active Pending
- 2025-09-12 JP JP2025152149A patent/JP2026009903A/ja active Pending
-
2026
- 2026-07-09 AU AU2026205443A patent/AU2026205443A1/en active Pending
- 2026-07-10 AU AU2026205504A patent/AU2026205504A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101625961B1 (ko) | 인터루킨-13 결합 단백질 | |
| JP2022512653A5 (enExample) | ||
| JP2022545196A5 (enExample) | ||
| CN104250302B (zh) | 抗pd‑1抗体及其应用 | |
| JP2021042257A5 (enExample) | ||
| JP7460551B2 (ja) | 抗ｈｅｒ２抗体 | |
| JP2023519099A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| JP2020500510A5 (enExample) | ||
| KR20120089659A (ko) | 치료용 ｄｌｌ4 결합 단백질 | |
| EP1945771A1 (en) | Fusion proteins that bind effector lymphocytes and target cells | |
| TW200531979A (en) | Inhibitors of type 2 vascular endothelial growth factor receptors | |
| CN118176215B (zh) | 新型抗l1cam抗体 | |
| JP2024517863A5 (enExample) | ||
| KR20190003625A (ko) | 인터페론 베타 항체 및 그의 용도 | |
| WO2019015282A1 (zh) | 靶向于白介素17a的抗体、其制备方法和应用 | |
| WO2022057875A1 (zh) | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 | |
| CN110790837A (zh) | 抗btla抗体 | |
| JP2025530888A5 (enExample) | ||
| CN104829716A (zh) | 用于治疗疾病的抗人sema4A抗体 | |
| CN117820475B (zh) | 针对il-17a的新型纳米抗体、药物、制备、方法及应用 | |
| EP3650469A1 (en) | Monoclonal antibody of targeted human tumor stem cells and application of monoclonal antibody | |
| CN113912720B (zh) | 一种抗人bcma单克隆抗体及应用 |